Oppenheimer & Co. Inc. Boosts Stake in Veru Inc. (NASDAQ:VERU)

Oppenheimer & Co. Inc. boosted its position in shares of Veru Inc. (NASDAQ:VERU - Free Report) by 181.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,120,586 shares of the company's stock after acquiring an additional 722,644 shares during the quarter. Oppenheimer & Co. Inc. owned 0.77% of Veru worth $729,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of VERU. Barclays PLC raised its position in Veru by 309.2% in the 3rd quarter. Barclays PLC now owns 184,777 shares of the company's stock valued at $142,000 after purchasing an additional 139,617 shares in the last quarter. Geode Capital Management LLC raised its position in Veru by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock valued at $2,261,000 after purchasing an additional 131,720 shares in the last quarter. SG Americas Securities LLC raised its position in Veru by 132.4% in the 4th quarter. SG Americas Securities LLC now owns 153,656 shares of the company's stock valued at $100,000 after purchasing an additional 87,528 shares in the last quarter. Choreo LLC raised its position in shares of Veru by 27.2% during the 4th quarter. Choreo LLC now owns 399,777 shares of the company's stock worth $260,000 after acquiring an additional 85,584 shares in the last quarter. Finally, 180 Wealth Advisors LLC raised its position in shares of Veru by 41.0% during the 4th quarter. 180 Wealth Advisors LLC now owns 293,350 shares of the company's stock worth $191,000 after acquiring an additional 85,350 shares in the last quarter. Institutional investors and hedge funds own 47.16% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of Veru in a research report on Thursday, January 2nd.

Insiders Place Their Bets

In other news, Director Michael L. Rankowitz purchased 95,279 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were bought at an average price of $0.55 per share, with a total value of $52,403.45. Following the completion of the transaction, the director now directly owns 195,279 shares in the company, valued at approximately $107,403.45. This represents a 95.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.90% of the stock is currently owned by corporate insiders.

Veru Price Performance

Shares of NASDAQ VERU traded down $0.01 during midday trading on Friday, hitting $0.51. 550,675 shares of the company's stock were exchanged, compared to its average volume of 4,090,531. Veru Inc. has a twelve month low of $0.48 and a twelve month high of $1.92. The company has a market cap of $75.14 million, a PE ratio of -1.97 and a beta of -0.46. The firm's fifty day simple moving average is $0.67 and its 200-day simple moving average is $0.73.

Veru (NASDAQ:VERU - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. Equities analysts anticipate that Veru Inc. will post -0.22 EPS for the current fiscal year.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.